Back to discover
Disease

chronic myelogenous leukemia, BCR-ABL1 positive

Late-stage therapeutic development
Also known as BCR-ABL Positive chronic myelogenous leukaemia, BCR-ABL Positive chronic myelogenous leukemia, CML, CML - chronic myelogenous leukaemia+20 more

BCR-ABL Positive chronic myelogenous leukaemia, BCR-ABL Positive chronic myelogenous leukemia, CML, CML - chronic myelogenous leukaemia, CML - chronic myelogenous leukemia, chronic granulocytic leukaemia, chronic granulocytic leukemia, chronic myelocytic leukaemia, chronic myelocytic leukemia, chronic myelogenous leukaemia, chronic myelogenous leukaemia (CML), chronic myelogenous leukemia, chronic myelogenous leukemia (CML), chronic myelogenous leukemias, chronic myeloid leukaemia, chronic myeloid leukemia, hematopoeitic - chronic myelocytic leukaemia (CML), hematopoeitic - chronic myelocytic leukemia (CML), leukemia, Philadelphia chromosome-positive, resistant to imatinib, Somatic mutation, leukemia, chronic myeloid, Philadelphia chromosome positive, somatic, myeloid leukemia, chronic, leukemia, chronic myelogenous, leukemia, chronic myeloid, leukemia, chronic myeloid, atypical.

20
Clinical trials
12
Associated genes
11
Related proteins
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 5 clinical trials expected to report results, the earliest in Q4 2027.
Upcoming Milestones
Clinical Milestones9View all 9
Results posted 3
Results expected 5
Recently completed 1
+1 more in the activity timeline below
Activity timeline9

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Nilotinibapproved

Approval — Nilotinib Accord is indicated for the treatment of: - adult and paediatric patients with… (2024)

Bosutinibapproved

Approval — Bosulif is indicated for the treatment of:• Adult and paediatric patients aged 6 years an… (2013)

Dasatinibapproved

Approval — Sprycel is indicated for the treatment of paediatric patients with: newly diagnosed Phil… (2006)

Clinical trials

7 sponsors · 0 new · 1 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
20
All trials
6
Active
1
Late-stage
6
Completed
Recently completed

A Phase II Study of the Combination of Decitabine, Venetoclax, and Ponatinib in Patients With Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase Chronic Myelogenous Leukemia

Phase 2 · Completed · M.D. Anderson Cancer Center

A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD

Phase 2 · Completed · Fred Hutchinson Cancer Center

Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib (BMS-354825)

Phase 2 · Completed · M.D. Anderson Cancer Center

Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML) and Myelofibrosis (MF)

Phase 2/3 · Completed · M.D. Anderson Cancer Center

Donor Lymphocyte Infusion for the Treatment of Malignancy After Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning - A Multi-center Trial

Phase 1/2 · Completed · Fred Hutchinson Cancer Center

A PHASE II STUDY OF G3139 (GENASENSE™, NSC # 683428 IND # 58842) + IMATINIB MESYLATE (GLEEVEC®, STI571) IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA

Phase 2 · Completed · National Cancer Institute (NCI)

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2024emaApproval — Nilotinib· Nilotinib Accord is indicated for the treatment of: - adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, - adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available, - paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. source ↗
2013emaApproval — Bosutinib· Bosulif is indicated for the treatment of:• Adult and paediatric patients aged 6 years and older with newly-diagnosed (ND) chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).• Adult and paediatric patients aged 6 years and older with CP Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.• Adult patients with accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. source ↗
2007emaApproval — Nilotinib· Tasigna is indicated for the treatment of: adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, paediatric patients with Philadelphia chromosome positive CML in chronic phase with resistance or intolerance to prior therapy including imatinib. Tasigna is indicated for the treatment of: adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available, paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. source ↗
2006emaApproval — Dasatinib· Sprycel is indicated for the treatment of paediatric patients with: newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib. newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy. Sprycel is indicated for the treatment of adult patients with: newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase; chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate; Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy. Sprycel is indicated for the treatment of paediatric patients with: newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

ABL10.83BCR0.82KIT0.70SETBP10.66PDGFRB0.65TET20.62FYN0.60LYN0.60BLK0.60SRC0.59HCK0.59FGR0.58

Disease biology

11 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Tyrosine-protein kinase ABL1via ABL10.83Breakpoint cluster region proteinvia BCR0.82Mast/stem cell growth factor receptor Kitvia KIT0.70Platelet-derived growth factor receptor betavia PDGFRB0.65Tyrosine-protein kinase Lynvia LYN0.60Proto-oncogene tyrosine-protein kinase Srcvia SRC0.59Tyrosine-protein kinase HCKvia HCK0.59Ephrin type-A receptor 2via EPHA20.58Ribonucleoside-diphosphate reductase subunit M2via RRM20.55Ribonucleoside-diphosphate reductase large subunitvia RRM10.54Cytidine deaminasevia CDA0.30

Reference

Authoritative identity, definition & identifiers.

Synonyms

BCR-ABL Positive chronic myelogenous leukaemia, BCR-ABL Positive chronic myelogenous leukemia, CML, CML - chronic myelogenous leukaemia, CML - chronic myelogenous leukemia, chronic granulocytic leukaemia, chronic granulocytic leukemia, chronic myelocytic leukaemia, chronic myelocytic leukemia, chronic myelogenous leukaemia, chronic myelogenous leukaemia (CML), chronic myelogenous leukemia, chronic myelogenous leukemia (CML), chronic myelogenous leukemias, chronic myeloid leukaemia, chronic myeloid leukemia, hematopoeitic - chronic myelocytic leukaemia (CML), hematopoeitic - chronic myelocytic leukemia (CML), leukemia, Philadelphia chromosome-positive, resistant to imatinib, Somatic mutation, leukemia, chronic myeloid, Philadelphia chromosome positive, somatic, myeloid leukemia, chronic, leukemia, chronic myelogenous, leukemia, chronic myeloid, leukemia, chronic myeloid, atypical

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.